ArticlePharmaceutical nanotechnology2022
Electrospun Nanofiber Composite for Levofloxacin in Ocular Drug Delivery.
Article in Pharmaceutical nanotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLevofloxacin is available in the form of an eye drop solution for the treatment of ocular bacterial infection and inflammatory diseases. Below 5% of the drug gets absorbed after topical application of eye drop. The major portion of administered drug either comes out from the eye or drains out by the nasolacrimal duct, which results in poor bioavailability.
objectiveWe aim to prepare a polymeric ocular insert containing levofloxacin as a drug prepared by the electrospinning technique that can release the drug for an extended duration.
methodsElectrospun nanofiber sheets were prepared using hydroxypropyl cellulose and polycaprolactone polymer. Drug content was analysed by HPLC. Nanosheet was examined by DSC and FTIR for compatibility study. Optimized nanosheet was further studied for weight uniformity, swellability index, surface pH, and in-vitro drug release. The morphology of the prepared sheets was examined using optical microscopy and SEM analysis.
resultsThe uniform, beadles, and continuous nanofibers were obtained by electrospinning. From the DSC and FTIR data, it was proved that drugs and polymers were compatible in nanosheets. Drug content and % drug loading in the electrospun sheets were found to be 101.70% and 4.33%, respectively. The thickness of the sheets was around 0.31± 0.04 mm and the swelling index was observed at 566.66% after 30 min. The surface pH of the ocular insert was found to be 6.81 and 6.83 after 30 min and 24 h., respectively. In-vitro drug release showed that 99% of the drug was released in 8 h.
conclusionA prepared nanocomposite sheet can be used for the sustained drug delivery of levofloxacin in ocular eye disease, reducing the dosing frequency and improving patient compliance.
Indexed as
Identifiers
40826524What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.